Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma.
HCC
ICI
PD-1/PD-L1 signaling pathway
immune tolerance
liver transplantation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
07
07
2023
medline:
8
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Primary liver cancer is one of the most common malignant tumors in China. The vast majority of primary liver cancer are hepatocellular carcinoma. Due to its high incidence and mortality from HCC, HCC has always been a feared type of cancer. Liver transplantation, as one of the important means to treat advanced liver cancer, has brought new hope to patients. However, as patients have been in a state of immunosuppression after liver transplantation, these patients face new problems of HCC recurrence and metastasis. A increasing number of studies have proved that blocking the PD-1/PD-L1 signaling pathway and restoring the immune killing inhibition of T cells can produce better therapeutic effects on tumors and chronic infectious diseases. As a promising treatment in the field of tumor immunotherapy, PD-1/PD-L1 inhibitors have achieved important results in liver cancer patients, but their application in liver transplantation patients is still highly controversial. This paper will introduce the mechanism of action of PD-1/PD-L1 signaling pathway and the current basic and clinical studies of PD-1/PD-L1 signaling pathway associated with immune response in HCC transplantation.
Identifiants
pubmed: 37545535
doi: 10.3389/fimmu.2023.1227756
pmc: PMC10399574
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
B7-H1 Antigen
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227756Informations de copyright
Copyright © 2023 Ju, Wang, Huang, Jiang, Gao, Xiong and Zhai.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Transplant. 2020 Mar;20(3):879-883
pubmed: 31550417
Transplant Rev (Orlando). 2021 Apr;35(2):100606
pubmed: 33636480
Am J Transplant. 2010 Jan;10(1):40-6
pubmed: 19889124
Nitric Oxide. 2022 Nov 1;128:1-11
pubmed: 35940533
Transplantation. 2023 Jul 1;107(7):1452-1462
pubmed: 36706163
J Autoimmun. 2010 Feb;34(1):1-6
pubmed: 19717280
Biosensors (Basel). 2022 Aug 08;12(8):
pubmed: 36005013
Inflammation. 2019 Feb;42(1):354-364
pubmed: 30255286
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7417-21
pubmed: 1323835
Int J Organ Transplant Med. 2015;6(2):45-54
pubmed: 26082828
J Immunother Cancer. 2018 Mar 6;6(1):18
pubmed: 29510697
World J Gastrointest Oncol. 2023 May 15;15(5):859-877
pubmed: 37275443
Ann Surg Oncol. 2010 Sep;17(9):2283-9
pubmed: 20204531
World J Gastroenterol. 2021 May 21;27(19):2394-2414
pubmed: 34040330
J Hepatol. 2016 Jun;64(6):1274-82
pubmed: 26941095
United European Gastroenterol J. 2018 Aug;6(7):970-973
pubmed: 30228883
Curr Top Microbiol Immunol. 2017;410:75-97
pubmed: 28929192
Sci Immunol. 2019 Mar 8;4(33):
pubmed: 30850393
Hepatology. 2018 Mar;67(3):1166-1168
pubmed: 29023959
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Semin Arthritis Rheum. 2003 Jun;32(6):345-69
pubmed: 12833244
J Transl Med. 2019 Dec 10;17(1):412
pubmed: 31823784
Hepatology. 2011 Jul;54(1):216-28
pubmed: 21503939
Cancer Res. 2019 Apr 1;79(7):1480-1492
pubmed: 30674531
Cancer J. 2014 Jul-Aug;20(4):262-4
pubmed: 25098286
Acta Oncol. 2018 Oct;57(10):1414-1418
pubmed: 29912605
Immunol Res. 2003;28(1):49-59
pubmed: 12947224
Gene. 1997 Sep 15;197(1-2):177-87
pubmed: 9332365
Pharmacol Ther. 2000 Nov;88(2):187-96
pubmed: 11150597
J Surg Oncol. 2013 Apr;107(5):517-22
pubmed: 23129549
J Transl Int Med. 2022 Mar 26;10(1):65-75
pubmed: 35702180
J Transl Int Med. 2022 Apr 02;10(1):56-64
pubmed: 35702189
J Infect. 2021 Sep;83(3):298-305
pubmed: 34324940
Front Microbiol. 2022 Sep 02;13:987324
pubmed: 36118247
Liver Int. 2015 Sep;35(9):2155-66
pubmed: 25752327
Transplantation. 1999 Feb 27;67(4):510-3
pubmed: 10071018
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Hepatology. 2018 Apr;67(4):1499-1515
pubmed: 28921638
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141886
Drug Discov Today. 2016 Jun;21(6):1027-36
pubmed: 27094104
Front Immunol. 2023 Feb 08;14:1127071
pubmed: 36845142
J Hepatol. 2023 Jun;78(6):1199-1215
pubmed: 37208106
Trends Immunol. 2005 Jun;26(6):292-4
pubmed: 15922943
Annu Rev Immunol. 1996;14:233-58
pubmed: 8717514
Am J Transplant. 2017 Jan;17 Suppl 1:174-251
pubmed: 28052604
Transplantation. 2007 Jul 27;84(2):214-22
pubmed: 17667813
Biomolecules. 2022 Sep 02;12(9):
pubmed: 36139065
J Exp Med. 1998 Dec 7;188(11):2163-73
pubmed: 9841929
BBA Clin. 2015 Apr 18;3:280-8
pubmed: 26673349
Infect Immun. 2015 Dec;83(12):4582-93
pubmed: 26371120
Immunol Rev. 2008 Apr;222:129-44
pubmed: 18363998
Transplantation. 2020 Mar;104(3):568-574
pubmed: 31517781
Front Oncol. 2022 Jul 19;12:931995
pubmed: 35965506
Am J Gastroenterol. 2017 Dec;112(12):1895-1896
pubmed: 29215617
Clin Cancer Res. 2018 Jul 1;24(13):3036-3045
pubmed: 29599411
Clin Cancer Res. 2022 Jan 1;28(1):5-12
pubmed: 34285059
Stem Cells. 2009 Aug;27(8):1734-40
pubmed: 19536809
Ann Oncol. 2020 Jun;31(6):724-744
pubmed: 32194150
Hepatobiliary Pancreat Dis Int. 2023 Jun;22(3):228-238
pubmed: 35613994
Immunol Rev. 2018 May;283(1):194-212
pubmed: 29664561
Gastroenterol Rep (Oxf). 2019 Dec 17;8(1):25-30
pubmed: 32104583
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Transplant Proc. 2014 Dec;46(10):3511-4
pubmed: 25498082